FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates specifically to the use of an IL-33 antagonist in the treatment of endometrial tissue disease, where this endometrial tissue disease is selected from endometriosis and adenomyosis. The use of a therapeutic agent containing an IL-33 antagonist as an active ingredient is provided for the relief of pain in an endometrial tissue disease, where this endometrial tissue disease is selected from endometriosis and uterine adenomyosis, in the treatment, prevention or relief of this disease. The use of a therapeutic agent containing an IL-33 antagonist as an active ingredient to inhibit adhesion of ectopic endometrial tissue and/or cysts to various organs in the treatment, prevention or alleviation of a disease endometrial tissue in a patient wherein this endometrial tissue disease is selected from endometriosis and uterine adenomyosis, wherein this IL-33 antagonist is selected from an anti-IL-33 antibody, an antibody directed against an IL-33 receptor, or a soluble IL-33 receptor. Use of an antibody selected from A10-1C04, A23-1A05, A25-2C02, A25-3H04, or A26-1F02 for the treatment, prevention, or amelioration of endometriosis or uterine adenomyosis.
EFFECT: therapeutic agent containing an IL-33 antagonist as an active ingredient is effective for relieving pain, for inhibiting adhesion of ectopic endometrial tissue and/or cysts to various organs in the treatment, prevention or alleviation of endometrial tissue disease in a patient where this endometrial disease tissues selected from endometriosis and adenomyosis of the uterus, and the use of an antibody selected from A10-1C04, A23-1A05, A25-2C02, A25-3H04 or A26-1F02 is effective for treating, preventing or relieving uterine endometriosis or adenomyosis.
8 cl, 6 dwg, 2 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION FOR PREVENTION OR TREATMENT OF IL-8-RELATED DISEASES | 2017 |
|
RU2766112C2 |
ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
ANTIGEN-BINDING MOLECULE INDUCING AN IMMUNE RESPONSE TO A TARGET ANTIGEN | 2012 |
|
RU2722829C2 |
METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
Authors
Dates
2023-03-13—Published
2018-08-31—Filed